Literature DB >> 6604389

Epidemiology of motor neuron disease in northern Sweden.

L Forsgren, B G Almay, G Holmgren, S Wall.   

Abstract

All cases of motor neuron disease (MND), encompassing amyotrophic lateral sclerosis (ALS), progressive bulbar paralysis (PBP) and progressive spinal muscular atrophy (PSMA), in northern Sweden, diagnosed between 1969-1980 have been analysed. 128 cases were found, corresponding to an average annual incidence rate of 1.67 per 100,000. The prevalence on December 31, 1980 was 4.8 per 100,000. Age-specific incidence rates were higher in the high age groups with a maximum at 60-64 years for males, at 70-74 years for females and at 65-69 years for the sexes combined. The median age at onset was 61 years. Clustering was not found in mining districts and overrepresentation of miners and stone treaters was not observed. Minor differences in incidence rates, as measured by the standardized morbidity ratio, SMR, were found between the inland, coastal and mountain areas. The median survival time after onset of disease was 32 months for ALS, 30 months for PBP and 70 months for PSMA. The combined survival rate for all MND cases was 28% after 5 years and 15% after 10 years. The male to female ratio was 1.1:1, and 4.7% were familial cases.

Entities:  

Mesh:

Year:  1983        PMID: 6604389     DOI: 10.1111/j.1600-0404.1983.tb04810.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  25 in total

1.  Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950.

Authors:  A M Chancellor; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 2.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

3.  The epidemiology of motor neurone disease in two counties in the southwest of England.

Authors:  Ibrahim Imam; Susan Ball; Dave Wright; C Oliver Hanemann; John Zajicek
Journal:  J Neurol       Date:  2010-01-22       Impact factor: 4.849

4.  Amyotrophic lateral sclerosis in Palermo, Italy: an epidemiological study.

Authors:  G Salemi; B Fierro; A Arcara; M Cassata; M G Castiglione; G Savettieri
Journal:  Ital J Neurol Sci       Date:  1989-10

5.  Haptoglobin groups in motor neuron disease.

Authors:  N Fröhlander; L Forsgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

6.  Age-specific ALS incidence: a dose-response meta-analysis.

Authors:  Benoît Marin; Andrea Fontana; Simona Arcuti; Massimilano Copetti; Farid Boumédiene; Philippe Couratier; Ettore Beghi; Pierre Marie Preux; Giancarlo Logroscino
Journal:  Eur J Epidemiol       Date:  2018-04-23       Impact factor: 8.082

Review 7.  Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Louisa Ng; Fary Khan; Carolyn A Young; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2017-01-10

8.  The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register.

Authors:  A M Chancellor; J M Slattery; H Fraser; R J Swingler; S M Holloway; C P Warlow
Journal:  J Neurol       Date:  1993-06       Impact factor: 4.849

9.  Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011.

Authors:  Kim Traxinger; Crystal Kelly; Brent A Johnson; Robert H Lyles; Jonathan D Glass
Journal:  Neurol Clin Pract       Date:  2013-08

Review 10.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.